{
    "nctId": "NCT06243432",
    "briefTitle": "Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer",
    "officialTitle": "Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study",
    "overallStatus": "RECRUITING",
    "conditions": "Advanced Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 yo\n* Histological diagnosis of HR+/HER2- advanced breast cancer\n* Immunohistochemical HER2 negative evaluation (0, 1+ or 2+ FISH-)\n* Immunohistochemical expression levels of estrogen and progesterone receptors\n* First line CDK4/6 inhibitor plus endocrine therapy stared up to 12/31/2020\n* Signing of informed consent approved by local Ethic Committee\n\nExclusion Criteria:\n\n* Absence of clinical and pathological data that would compromise the definition of the study endpoints\n* HER2 positive (ICH 2+ and FISH positive or HER2 3 +) or triple negative disease\n* Previous chemotherapy for treatment of metastatic disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}